Apomorphine subcutaneous infusion is an effective treatment for Parkinson patients whose motor fluctuations are poorly controlled by conventional therapies. This was shown by the large-scale TOLEDO ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

Credit: Thinkstock. SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump. The Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act ...

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

LONDON, Aug. 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology [1]. Treatment with APO-go ...

The benefits of the dopamine agonist apomorphine in Parkinson's disease have finally been confirmed in a randomized controlled trial, although the drug has been used in the condition for many years.

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...

Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go ® /MOVAPO ® (apomorphine) subcutaneous infusion in Parkinson's disease (PD) patients whose motor ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

Amsterdam (ptp008/27.06.2017/08:00) A new study proves that apomorphine subcutaneous infusions reduce OFF time in Parkinson patients, in other words times of motor deficit. "Our results provide high ...